Integrated Filing — IndAS
General information about company
| Scrip Code |
531768 |
| NSE Symbol |
POLYMED |
| MSEI Symbol |
NA |
| ISIN |
INE205C01021 |
| Name of company |
POLY MEDICURE LIMITED |
| Type of company |
Main Board |
| Class of security |
Equity |
| Date of start of financial year |
01-04-2025 |
| Date of end of financial year |
31-03-2026 |
| Date of board meeting when results were approved |
05-02-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed
to the exchange |
29-01-2026 |
| Description of presentation currency |
INR |
| Level of rounding used in financial results |
Lakhs |
| Reporting Type |
Quarterly |
| Reporting Quarter |
Third quarter |
| Nature of report standalone or consolidated |
Consolidated |
| Whether results are audited or unaudited for the quarter ended |
Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended |
Unaudited |
| Segment Reporting |
Single segment |
| Description of single segment |
Manufacturing of Medical Devices |
| Start date and time of board meeting |
05-02-2026 12:45:00 |
| End date and time of board meeting |
05-02-2026 14:35:00 |
| Whether cash flow statement is applicable on company |
|
| Type of cash flow statement |
|
| Declaration of unmodified opinion or statement on impact of audit qualification |
Not applicable |
Financial Results Ind-AS
Amount in (Lakhs)
| Particulars |
3 months/ 6 months ended (dd-mm-yyyy) |
Year to date figures for current period ended (dd-mm-yyyy) |
| A |
Date of start of reporting period |
01-10-2025 |
01-04-2025 |
| B |
Date of end of reporting period |
31-12-2025 |
31-12-2025 |
| C |
Whether results are audited or unaudited |
Unaudited |
Unaudited |
| D |
Nature of report standalone or consolidated |
Consolidated |
Consolidated |
| 1 |
Income |
|
Revenue from operations |
49,365.55 |
1,34,074.78 |
|
Other income |
2,626.34 |
10,232.57 |
|
Total income |
51,991.89 |
1,44,307.35 |
| 2 |
Expenses |
| (a) |
Cost of materials consumed |
14,616.59 |
44,430.90 |
| (b) |
Purchases of stock-in-trade |
158.36 |
367.63 |
| (c) |
Changes in inventories of finished goods,
work-in-progress and stock-in-trade |
801.15 |
(2,933.60) |
| (d) |
Employee benefit expense |
11,520.27 |
27,914.30 |
| (e) |
Finance costs |
595.92 |
1,188.21 |
| (f) |
Depreciation, depletion and amortisation expense
|
2,875.58 |
7,694.42 |
| (f) |
Other Expenses |
| 1 |
Research and development expenses |
595.82 |
2,044.52 |
| 2 |
Other Expenses |
10,555.10 |
29,093.14 |
|
Total other expenses |
11,150.92 |
31,137.66 |
|
Total expenses |
41,718.79 |
1,09,799.52 |
| 3 |
Total profit before exceptional items and tax |
10,273.10 |
34,507.83 |
| 4 |
Exceptional items |
(680.40) |
(680.40) |
| 5 |
Total profit before tax |
9,592.70 |
33,827.43 |
| 6 |
Tax expense |
|
| 7 |
Current tax |
2,648.42 |
7,601.87 |
| 8 |
Deferred tax |
31.94 |
1,054.13 |
| 9 |
Total tax expenses |
2,680.36 |
8,656.00 |
| 10 |
Net movement in regulatory deferral account balances related to profit or loss and
the related deferred tax movement |
0.00 |
0.00 |
| 11 |
Net Profit Loss for the period from
continuing operations |
6,912.34 |
25,171.43 |
| 12 |
Profit (loss) from discontinued operations before tax |
0.00 |
0.00 |
| 13 |
Tax expense of discontinued operations |
0.00 |
0.00 |
| 14 |
Net profit (loss) from discontinued
operation after tax |
0.00 |
0.00 |
| 15 |
Share of profit (loss) of associates and joint ventures accounted for using equity
method |
168.55 |
397.47 |
| 16 |
Total profit (loss) for period |
7,080.89 |
25,568.90 |
| 17 |
Other comprehensive income net of taxes |
2,251.90 |
2,158.79 |
| 18 |
Total Comprehensive Income for the period |
9,332.79 |
27,727.69 |
| 19 |
Total profit or loss, attributable to
|
|
|
|
Profit or loss, attributable to owners of parent |
7,093.02 |
25,584.78 |
|
Total profit or loss, attributable to non-controlling interests |
(12.13) |
(15.88) |
| 20 |
Total Comprehensive income for the period attributable to |
|
|
|
Comprehensive income for the period attributable to owners of parent |
2,251.78 |
2,158.69 |
|
Total comprehensive income for the period attributable to owners of parent non-controlling
interests |
0.12 |
0.10 |
| 21 |
Details of equity share capital |
|
|
Paid-up equity share capital |
5,067.97 |
5,067.97 |
|
Face value of equity share capital |
5 |
5 |
| 27 |
Details of debt securities |
|
| 22 |
Reserves excluding revaluation reserve |
|
|
| 23 |
Earnings per share |
|
| i |
Earnings per equity share for continuing operations |
|
|
Basic earnings (loss) per share from continuing operations |
7 |
25.25 |
|
Diluted earnings (loss) per share from continuing operations |
6.99 |
25.22 |
| ii |
Earnings per equity share for discontinued operations |
|
|
Basic earnings (loss) per share from discontinued operations |
0 |
0 |
|
Diluted earnings (loss) per share from discontinued operations |
0 |
0 |
| ii |
Earnings per equity share |
|
|
Basic earnings (loss) per share from continuing
and discontinued operations |
7 |
25.25 |
|
Diluted earnings (loss) per share from
continuing and discontinued operations |
6.99 |
25.22 |
| 24 |
Debt equity ratio |
|
|
| 25 |
Debt service coverage ratio |
|
|
| 26 |
Interest service coverage ratio |
|
|
| 27 |
Disclosure of notes on financial results |
|
Remarks
Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Amount in (Lakhs)
| Particulars |
3 months/ 6 month ended (dd-mm-yyyy) |
Year to date figures for current period
ended (dd-mm-yyyy) |
| Date of start of reporting period |
01-10-2025 |
01-04-2025 |
| Date of end of reporting
period |
31-12-2025 |
31-12-2025 |
| Whether results are audited
or unaudited |
Unaudited |
Unaudited |
| Nature of report standalone or
consolidated |
Consolidated |
Consolidated |
| 1 |
Segment Revenue (Income) |
|
(net sale/income from each segment should
be disclosed) |
|
Total Segment Revenue |
|
|
|
Less: Inter segment revenue |
|
|
|
Revenue from operations |
|
|
| 2 |
Segment Result |
|
Profit (+) / Loss (-) before tax and
interest from each segment |
|
Total Profit before tax |
|
|
|
i. Finance cost |
|
|
|
ii. Other Unallocable Expenditure net off Unallocable income |
|
|
|
Profit before tax |
|
|
| 3 |
(Segment Asset - Segment Liabilities)
|
|
Segment Asset |
|
Total Segment Asset |
|
|
|
Un-allocable Assets |
null |
null |
|
Net Segment Asset |
null |
null |
| 4 |
Segment Liabilities |
|
Segment Liabilities |
|
Total Segment Liabilities |
|
|
|
Un-allocable Liabilities |
null |
null |
|
Net Segment Liabilities |
null |
null |
|
Disclosure of notes on segments |
|
Other Comprehensive Income
Amount in (Lakhs)
| Particulars |
3 months/ 6 months ended (dd-mm-yyyy) |
Year to date figures for current period ended (dd-mm-yyyy) |
| A |
Date of start of reporting period |
01-10-2025 |
01-04-2025 |
| B |
Date of end of reporting period |
31-12-2025 |
31-12-2025 |
| C |
Whether results are audited or unaudited |
Unaudited |
Unaudited |
| D |
Nature of report standalone or consolidated |
Consolidated |
Consolidated |
|
Other comprehensive income [Abstract] |
|
| 1 |
Amount of items that will not be reclassified to profit and loss |
|
| 1 |
Remeasurement of defined benefit obligations |
29.93 |
(53.74) |
|
Total Amount of items that will not be reclassified to profit and loss |
29.93 |
(53.74) |
| 2 |
Income tax relating to items that will not be reclassified to profit or loss |
7.53 |
(13.53) |
| 3 |
Amount of items that will be reclassified to profit and loss |
|
| 1 |
Exchange difference on translation of financial statements of foreign subsidiaries |
2,229.50 |
2,199.00 |
|
Total Amount of items that will be reclassified to profit and loss |
2,229.50 |
2,199.00 |
| 4 |
Income tax relating to items that will be reclassified to profit or loss |
0.00 |
0.00 |
| 5 |
Total Other comprehensive income |
2,251.90 |
2,158.79 |